Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2018-07
-
br Conclusions Several lines of evidence have been establish
2024-11-04

Conclusions Several lines of evidence have been established, which support the adenosine kinase hypothesis of epileptogenesis, which is based on a sequence of events leading from acute GSK2194069 injury to initial downregulation of ADK, rise in extracellular adenosine, changes in astrocytic aden
-
Brain biopsy was performed from the
2024-11-04

Brain biopsy was performed from the white matter lesion around the posterior horn of the right lateral ventricle, and revealed inflammatory demyelination, such as myelin loss with relative preservation of axons, astrocytosis immnolabeled by Candesartan against glial fibrillary acidic protein, infil
-
br Identification of the kinase
2024-11-01

Identification of the kinase that phosphorylates P450c17 The first Ser/Thr kinase that phosphorylates P450c17 was identified only recently. Of the 518 kinases in the human ‘kinome’ 278 are Ser/Thr kinases (Manning et al., 2002), but microarrays identified only 145 Ser/Thr kinases in human NCI-H29
-
GNE-7915 For the NSCLC patients with
2024-11-01

For the NSCLC patients with EGFR-activating mutations, EGFR-TKIs (gefitinib and erlotinib) are effective clinical therapies [21], [22]. However, approximately 10% of patients harboring EGFR-sensitizing mutations exhibit intrinsic resistance, and up to 40% do not attain a major response to treatment
-
br Introduction Arginase deficiency is a rare metabolic
2024-11-01

Introduction Arginase deficiency is a rare metabolic disorder resulting from a loss of arginase 1 (ARG1), the final enzyme in the urea cycle, which is the major pathway for the detoxification of ammonia in terrestrial mammals. ARG1 is expressed most prevalently in hepatocytes and red blood cells.
-
The contractility index showed positive inotropic effects of
2024-11-01

The contractility index showed positive inotropic effects of apelin in both doses at min 5 (Fig. 3, Fig. 5). Although the mean arterial pressure did not recover to the baseline, the contractility index increased, the relaxation index (tau) and ±dp/dt max returned back to their baseline, and left ven
-
br Conclusions In summary KLA isolated from K senegalensis
2024-11-01

Conclusions In summary, KLA isolated from K. senegalensis exerted the anti-inflammatory activity via inhibiting the activation of NF-κB, AP-1, AKT and upregulating p38 MAPK/Nrf2/HO-1 signaling in LPS-stimulated RAW 264.7 and BV-2 Cyclophosphamide monohydrate (Fig. 9). These properties provide a
-
br Conclusions br Acknowledgments br Introduction The surfac
2024-11-01

Conclusions Acknowledgments Introduction The surface water bodies are affected by effluents containing pollutants from wastewater treatment plants, storm water overflows and run-off from non-point sources like agricultural land and urban city surfaces. This relates to land-based sources occ
-
br Perspective AA LA and other PUFAs
2024-10-31

Perspective AA, LA and other PUFAs and their lipid metabolites play an important role in human diseases. 12/15-LOX which is the metabolic enzyme of them plays an important role in the pathogenesis-related diseases such as atherosclerosis, diabetic nephropathy, neurological diseases and other path
-
br Development of lorlatinib from crizotinib to a clinical
2024-10-31

Development of lorlatinib from crizotinib (1) to a clinical candidate (6) Xalkori (1, PF-02341066, crizotinib), was the first-in-class ALK inhibitor approved by the Unites States Food and Drug Administration (FDA) in 2011 as a first-line treatment for ALK+- NSCLC patients. This section describes
-
ghrelin receptor antagonist br Regulation of AHR Activity AH
2024-10-31

Regulation of AHR Activity AHR activity is regulated in various ways. First, AHR protein levels are controlled via ubiquitin-mediated proteosomal degradation: Ligand binding induces AHR ubiquitination and subsequent degradation by the proteasome [5]. AIP, a component of the AHR chaperone complex,
-
br Methods br Results br Discussion
2024-10-31

Methods Results Discussion Adiponectin is naturally expressed and secreted exclusively from adipocytes, and adiponectin levels and its isoforms in circulation have recently been reported to highly associate with human coronary artery disease (CAD) [46], [47], [48], [49], these studies clear
-
br New AMPK activators Fenofibrate is a
2024-10-31

New AMPK activators Fenofibrate is a drug of the fibrate class used for the treatment of dyslipidemia [53] but is also an agent that could alleviate DN-induced alterations through AMPK activation (Fig. 2). Streptozotocin-induced diabetic rats treated with fenofibrate improved in not only renal fu
-
That disassembling actin filaments transport chromosomes
2024-10-31

That disassembling ptio filaments transport chromosomes towards the spindle in oocytes may be surprising at first sight. On the other hand, it is well established that chromosome movement during anaphase is driven by the depolymerization of microtubules [20]. It will be interesting to investigate th
-
br Conflict of interest br Financial support br Acknowledgme
2024-10-31

Conflict of interest Financial support Acknowledgments This work was supported by the Japanese Millennium project. We thank all members of the Center for Genomic Medicine of RIKEN and Dainippon-Sumitomo Pharma Co., Ltd. for supporting this study. We are also grateful to members of the Hiros
14345 records 63/957 page Previous Next First page 上5页 6162636465 下5页 Last page